In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually sickness progression or the participants are unable to tolerate the study drugs. - "Our study unveiled the essential job in the KLF16/MYC regulatory axis in https://raymondtfpak.blogmazing.com/31299238/what-does-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-mean